About Affymetrix

Stock Quote

Security
AFFX (Common Stock)
$13.99
 (0.00%
Current Day's High
14.09
Current Day's Low
13.96
Current Day's Volume
0
Last Trade
Feb 11 16 4:00 p.m. ET
Exchange
NASDAQ

The stock price performance shown on the quote above is not necessarily indicative of future price performance

Investors

Investor Relations Contact

Doug Farrell
VP Investor Relations & Treasury
Tel. 408-731-5285
Fax. 408-731-5750
investor@affymetrix.com

Investor Kit

Download Documentation2014 Annual Report
Download Documentation2015 Proxy

Recent News

TitleDate
Bio-Genesys and Affymetrix Partner to Offer Animal Genomic Testing Services to Professional Farming Operations
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 12, 2016-- Affymetrix, Inc. (NASDAQ:AFFX) and United Kingdom-based Bio-Genesys Diagnostics announced today that they have entered a partnership to offer commercial genotyping services. Under the terms of the agreement, the genetic testing services offered by Bio-Genesys Diagnostics for cattle, pigs, goats, sheep, and camelids will be run exclusively on Affymetrix’s technology. The partnership leverages th... 
01/12/16
Thermo Fisher Scientific to Acquire Affymetrix
Strengthens Leadership in Biosciences and Genetic Analysis Significantly Expands Portfolio of Antibodies and Assays for High-Growth Flow Cytometry and Single-Cell Biology Applications Adds Complementary Genetic Analysis Products Serving Research, Clinical and Applied Markets Offers Opportunity to Leverage Thermo Fisher’s Commercial and Geographic Scale Creates Attractive... 
01/08/16
Affymetrix Expands Agrigenomics Genotyping Portfolio with New Targeted Sequencing Solution and Array Formats
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 7, 2016-- Affymetrix, Inc. (NASDAQ:AFFX) is introducing several new agrigenomic genotyping solutions this week at the annual Plant and Animal Genome Conference (PAG XXIV). Following the company’s acquisition of Eureka Genomics in mid-2015, Affymetrix is introducing Eureka™ Genotyping Solution for low-cost, low-plex genotyping by sequencing (GBS). The company is also introducing two new array configuration... 
01/07/16
Affymetrix and Reveal Biosciences Partner to Offer RNA ISH Tissue Staining, Imaging, and Image Analysis Services
SANTA CLARA, Calif. & SAN DIEGO--(BUSINESS WIRE)--Dec. 2, 2015-- Affymetrix Inc. (NASDAQ:AFFX) and Reveal Biosciences LLC, an advanced tissue technologies company, today announced a partnership agreement through which Reveal will use Affymetrix ViewRNA® ISH products for tissue samples to provide RNA in situ hybridization (ISH) staining, imaging, and quantification services using the company’s proprietary image analysis software, ImageDx... 
12/02/15
Affymetrix Reports New Employee Stock Grants
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 23, 2015-- Affymetrix (NASDAQ:AFFX) today announced that equity awards were made to 5 new non-executive officer employees as inducement to join Affymetrix. The equity awards were granted pursuant to NASDAQ Marketplace Rule 5635(c)(4) under the Affymetrix, Inc. 2012 Inducement Plan, which the Board of Directors of Affymetrix adopted for the granting of inducement equity awards to new employees. ... 
11/23/15
USDA, Aviagen, Hendrix Genetics, and Affymetrix Launch Axiom® Turkey Genotyping Array for Improved Breeding Outcome
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 19, 2015-- Affymetrix, Inc. (NASDAQ: AFFX) introduces Axiom® Turkey Genotyping Array, developed in collaboration with the United States Department of Agriculture – Agricultural Research Service (USDA-ARS) along with Aviagen and Hendrix Genetics. The array will help breeders better understand the genetics of turkeys in order to improve meat characteristics and health. It will enable scientist... 
11/19/15
Affymetrix and XRGenomics LTD to Collaborate on Development of a New Generation of Diagnostic Tests for Age-Related Diseases
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 5, 2015-- Affymetrix, Inc. (NASDAQ: AFFX) and XRGenomics LTD, a UK based biotechnology company, announced today that they will collaborate on research and development of a new generation of diagnostic tests for age-related diseases. Over 50% of healthcare costs are spent on those aged 65 and older and according to the G8 Summit 2013, age-related diseases could bankrupt Western medicine by 2050. New ... 
11/05/15
Affymetrix Reports Third Quarter 2015 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 28, 2015-- Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the third quarter of 2015. Results for the three months ended September 30, 2015: Total revenue was $86.5 million, compared to $87.1 million in third quarter of 2014. Reported revenue decreased 0.6%, however, increased 3.6% on a constant currency basis. ... 
10/28/15
Affymetrix and Athletigen Partner to Advance Genetics in Human Athletic Performance
SANTA CLARA, Calif. & HALIFAX, Nova Scotia--(BUSINESS WIRE)--Oct. 27, 2015-- Affymetrix Inc. (NASDAQ: AFFX) and Athletigen Technologies Inc., a direct-to-consumer sports genetics company, today announced a global partnership agreement. Under the agreement, Athletigen will use Affymetrix Axiom® genotyping platform for its sports-related DNA analysis service. This Smart News Release features multimedia. View the full release here: http://www.busines... 
10/27/15
Affymetrix and Luminex Announce Distribution Agreement for Multiplexed Assay Instrument Platform
SANTA CLARA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Oct. 15, 2015-- Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ: LMNX) today announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s MAGPIX®, Luminex® 200™ and FLEXMAP 3D® multiplexed assay platforms in specified countries in the Americas, Asia and Europe. Affymetrix will sell the Luminex instruments together with ... 
10/15/15
Affymetrix Genotyping Array Technology Powers Newly Published Work on Transplantation Genetics
Papers in Transplantation and Genomic Medicine Describe Creation and Testing of Customized Transplant Array Santa Clara, CA, October 6, 2015 – Affymetrix, Inc. (NASDAQ: AFFX) announced today that its Axiom® high-throughput genotyping technology was instrumental in two transplantation peer-reviewed publications issued this month by an international team of surgeons and scientists. The consortium – International Genetics and Translational Research in Transplantation Network (iGeneTRAiN) –... 
10/06/15
New Affymetrix HLA Analysis Software Quickly Delivers High-Resolution HLA Types From Genotyping Data
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 6, 2015-- Affymetrix (NASDAQ: AFFX) introduces Axiom™ HLA Analysis software for automated, high-resolution human leukocyte antigen (HLA) typing from any genotyping dataset containing coverage of the extended major histocompatibility complex (MHC) region. The software’s unique imputation algorithm enables 4-digit HLA typing from genome-wide association studies (GWAS), combining genotyping and high-resoluti... 
10/06/15
Affymetrix Introduces Axiom Transplant Genotyping Array for Genomic Profiling of Immune-Related Markers
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 6, 2015-- Affymetrix (NASDAQ:AFFX) introduces Axiom® Transplant Genotyping Array, designed in collaboration with an international team of surgeons and scientists for research studies to improve transplantation success and individualize donor/patient selection and treatment. The array comprises ~ 780,000 markers, including over 30,000 variants that may contribute to transplant rejection or other complicati... 
10/06/15
Affymetrix to Report Third Quarter 2015 Operating Results on Wednesday October 28, 2015
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 5, 2015-- Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will report operating results for the third quarter of 2015 after market close on Wednesday October 28, 2015. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, investors and othe... 
10/05/15
New 384-well Assay from Affymetrix Delivers High-Throughput, PCR-free Gene Expression Analysis
SANTA CLARA, Calif., September 22, 2015 –Affymetrix (Nasdaq: AFFX) announces the extension of its QuantiGene® Singleplex Assay for PCR-free gene expression measurement to include a 384-well format that is easily automatable for high-throughput compound screening. The easy-to-use, high-sensitivity assay measures gene expression with minimal sample preparation, using branched DNA for signal amplification. A key feature of the assay is that it does not require RNA or DNA purification, revers... 
09/22/15

Receive Email Alerts

Sign up to receive e-mail alerts whenever Affymetrix posts new information to the site. Just enter your e-mail address and click Submit.


Data provided by Nasdaq. Minimum 15 minutes delayed.

Back to Top >